RecruitingNCT00360646

Drug-Induced Liver Injury (DILI) Network Retrospective

Idiosyncratic Liver Injury Associated With Drugs (ILIAD): A Retrospective Study


Sponsor

Duke University

Enrollment

400 participants

Start Date

Sep 1, 2004

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study is to establish retrospectively a nationwide registry of patients who have suffered drug-induced liver injury (DILI), and to collect, immortalize, and store serum, DNA, and lymphocytes from these patients. ILIAD will serve as a resource for subsequent mechanistic investigations into the basis of severe idiosyncratic DILI. The primary goal of the ILIAD protocol is to create: (a) a clinical database consisting of individuals who have experienced severe DILI and the relevant clinical data concerning the episode of DILI; and, (b) to create a bank of biological specimens obtained from these individuals. These biological specimens will be DNA, plasma, and immortalized lymphocytes. Immortalized lymphocytes will provide unlimited amounts of genomic DNA for study as well as living immune cells for phenotyping studies. A secondary goal of the ILIAD protocol is to maintain a registry of cases in the ILIAD database so that they may be recontacted in the future. It is expected that this will facilitate additional studies exploring the mechanisms of DILI.


Eligibility

Min Age: 2 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with drug-induced liver injury. The study is currently recruiting participants at 6 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(6)

University of Southen California

Los Angeles, California, United States

Indiana University

Indianapolis, Indiana, United States

NIH Clinical Site

Bethesda, Maryland, United States

University of Michigan

Ann Arbor, Michigan, United States

Univeristy of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States

Thomas Jefferson

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT00360646


Related Trials